News

FierceBiotech7y
OSE, Memorial Sloan Kettering Cancer Center ally to advance anti-CD127 NSCLC candidate
OSE Immunotherapeutics has teamed up with Memorial Sloan Kettering Cancer Center (MSK ... OSE thinks OSE-703 can improve outcomes in NSCLC through antibody-dependent cell-mediated cytotoxicity ...
ascopubs.org1y
Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research
Instead, OSE users can fulfill most of the common requests ... Human Specimen Banking Grant U24CA196173, NCTN Statistics and Data Center Grant U10CA180899 of the Children's Oncology Group (COG) from ...
Business Wire3y
OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) presented the first positive preclinical efficacy data on its novel myeloid ...
Business Wire3y
OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia
OSE Immunotherapeutics ... FR0012127173; Mnemo: OSE) presented the first preclinical data on anti-leukemic efficacy of ... Christian-Albrechts University Kiel and University Medical Center ...
Morningstar1mon
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab NANTES, France – April 9, 2025, 7:30 a.m. CET - OSE ...